Results 41 to 50 of about 2,974 (211)
The Clinical Efficacy of Multidose Oritavancin: A Systematic Review
Antibiotics, 2023 Oritavancin (ORI) is a semisynthetic lipoglycopeptide approved as a single 1200 mg dose intravenous infusion for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) caused by Gram-positive organisms in adults.
Giammarco Baiardi +8 more
doaj +1 more source
An in vitro evaluation of the efficacy of tedizolid: implications for the treatment of skin and soft tissue infections [PDF]
, 2018 Skin and soft tissue infections (SSTI) are among the most commonly occurring infections and evidence suggests that these are increasing world-wide.
Aleryan, Muna +4 more
core +2 more sources
Pharmacokinetic Interactions for Drugs with a Long Half-Life—Evidence for the Need of Model-Based Analysis [PDF]
, 2015 Pharmacokinetic drug-drug interactions (DDIs) can lead to undesired drug exposure, resulting in insufficient efficacy or aggravated toxicity. Accurate quantification of DDIs is therefore crucial but may be difficult when full concentration-time profiles ...
Björn Clauson +4 more
core +1 more source
Oritavancin - Ein langwirksames Reserveantibiotikum
, 2023 Oritavancin ist ein Antibiotikum aus der Klasse der semisynthetischen Lipoglykopeptide, das intravenös appliziert wird und gegen grampositive Erreger wirkt. Es zeichnet sich vor allem durch seine lange Halbwertszeit aus, die eine wöchentliche Gabe ermöglicht.
Sendi, Parham, Martinez, Aurélien E.
openaire +2 more sources
Oritavancin Pharmacokinetics and Bone Penetration in Rabbits [PDF]
Antimicrobial Agents and Chemotherapy, 2015 ABSTRACT The pharmacokinetics and bone concentrations of oritavancin were investigated after a single intravenous dose was administered to rabbits. The pharmacokinetic profile of oritavancin in rabbits showed that it is rapidly distributed to bone tissues, with concentrations remaining stable for up to 168 h, the last measured time point ...
Dario Lehoux +6 more
openaire +2 more sources
Saarvienin A—A Novel Glycopeptide with Potent Activity against Drug‐Resistant Bacteria
Angewandte Chemie, Volume 137, Issue 25, June 17, 2025.A structurally distinct glycopeptide, saarvienin A, represents a new family of glycopeptide antibiotics consisting of five sugar/aminosugar units connected to a halogenated peptide core. Saarvienin A overcomes vancomycin resistance and shows strong activity against drug‐resistant Gram‐positive bacteria, in particular, high‐priority pathogens such as ...
Amninder Kaur +7 more
wiley +2 more sources
IDCases, 2020 A patient with a prosthetic joint infection (PJI) complicated with deep surgical site infection due to vancomycin-susceptible Enterococcus faecalis. The initial treatment consisted of 10 days with daptomycin plus ampicillin.
Jullian P. Nguyen +7 more
doaj +1 more source
Susceptibility testing and reporting of new antibiotics with a focus on tedizolid: an international working group report [PDF]
, 2017 Inappropriate use and overuse of antibiotics are among the most important factors in resistance development, and effective antibiotic stewardship measures are needed to optimize outcomes.
Ana Cristina Gales +8 more
core +5 more sources
Регуляторные исследования и экспертиза лекарственных средств, 2023 In recent years, glycopeptide antibiotics have been widely used to treat severe bacterial infections. The long-term use of first-generation antibiotics of this group (vancomycin, teicoplanin) has contributed to the emergence of bacteria resistant to them.
O. N. Vysochanskaya +2 more
doaj +1 more source
Clostridium difficile spores and its relevance in the persistence and transmission of the infection [PDF]
, 2014 Indexación: Web of Science; Scielo.Clostridium difficile es un patógeno anaerobio, formador de esporas y el agente etiológico más importante de las diarreas asociadas a antimicrobianos, tanto nosocomiales como adquiridas en la comunidad.
Barra-Carrasco, Jonathan +5 more
core +1 more source